Comments on the poll question "Funding FDA Inspections"
Article
Your comments to the poll question: The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
Your comments
"Regarding inspection fees, one approach for establishing fees would be to assess the actual cost or the average cost for doing the inspections after let’s say 100 inspections at various size manufacturing plants. The FDA could then establish, based on the size of the manufacturing facility, a fixed fee. The larger manufacturing facilities might have a larger fee. Many local governments set their fees based upon a historical average of what it costs to perform the task. The goal is that the local municipality is able to recover their out-of-pocket costs and not make any profit from the fees."
The question
The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
1. On a facility basis, based on the size of the manufacturing facility. 2. On a company basis, based on company revenues. 3. On a company basis, based on the number of manufacturing facilities operated by the company. 4. A flat fee for all companies with pharmaceutical manufacturing facilities.
Click here to submit a comment. Go to the poll archive to see past questions and results.
Comments on the poll question "Funding FDA Inspections"
Your comments to the poll question: The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
Your comments
The question
The proposed Food and Drug Administration Globalization Act of 2008 recommends imposing a fee for inspections to fund the cost of FDA inspections (both domestic and foreign inspections). If such a measure is adopted, how should the fee be assessed?
1. On a facility basis, based on the size of the manufacturing facility.
2. On a company basis, based on company revenues.
3. On a company basis, based on the number of manufacturing facilities operated by the company.
4. A flat fee for all companies with pharmaceutical manufacturing facilities.
Click here to submit a comment. Go to the poll archive to see past questions and results.
FDA Grants Fast Track Designation to Teva Celiac Disease Candidate
Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Companies Reveal Their Next Moves in Manufacturing
In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.
Transformations in Drug Development for Cell and Gene Therapies
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
End-to-end regulatory CDMO solutions: development, manufacturing, and approval (May 2025)
Exploring the need for dose-flexible manufacturing
FDA Grants Fast Track Designation to Teva Celiac Disease Candidate
Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Companies Reveal Their Next Moves in Manufacturing
In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.
Transformations in Drug Development for Cell and Gene Therapies
As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
End-to-end regulatory CDMO solutions: development, manufacturing, and approval (May 2025)
Exploring the need for dose-flexible manufacturing